Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2025 Q3

On November 7, 2025, Stonegate Capital Partners updated its coverage on NU Skin Enterprises Inc. (NYSE: NUS), following the company's Q3 2025 financial results. NU Skin reported revenues of $364.2 million, adjusted net income of $17.1 million, and adjusted earnings per share (EPS) of $0.34. These figures fell short of Stonegate's estimates of $374.2 million for revenue and $14.7 million for adjusted net income, although the EPS exceeded expectations, aligning with the higher end of guidance.

Despite revenue results at the lower end of the company's forecasts, NU Skin maintained robust operational efficiencies, posting a gross margin of 70.5%. The company reported a notable reduction in selling expenses, which were down to 35.8% company-wide and 41.7% within its core business. NU Skin's Rhyz segment contributed significantly, generating $51.6 million in revenue, split between $47.6 million from manufacturing and $4 million from Rhyz Other.

Management emphasized the company’s growth in Latin America, highlighting improvements across various segments and the importance of disciplined spending in achieving near top-tier EPS results, even in a challenging macroeconomic climate. They also announced plans for a limited preview of the Prysm iO product in late 2025 and expressed intentions to commence pre-market activities in India, anticipating a full launch in 2026.

Finally, NU Skin’s cash position stood at $251.7 million, and management narrowed guidance for Q4 and the full year in 2025 while focusing on sustaining margin improvements. Stonegate Capital Partners reiterated NU Skin's strategic initiatives and potential for growth moving forward.

Investors are closely monitoring the latest report from Stonegate Capital Partners regarding NU Skin Enterprises Inc. (NYSE: NUS), as the company presents mixed signals amidst a challenging macroeconomic backdrop. For Q3 2025, NU Skin reported revenues of $364.2 million, adjusted net income of $17.1 million, and an adjusted earnings per share (EPS) of $0.34. While the revenue fell short of the projected $374.2 million, the EPS exceeded estimates of $0.30, highlighting a resilient bottom line despite sluggish top-line growth.

The key highlight from the report is the robust gross margin of 70.5% and a significant reduction in selling expenses to 35.8%, indicating that NU Skin is managing its operational costs effectively. These indicators suggest that the company is focusing on strategic efficiency, which bodes well for its profitability in the face of revenue pressures. Additionally, the double-digit growth in Latin America is a promising expansion signal, likely driven by increasing market penetration and effective execution of sales strategies.

Management's focus on disciplined spending and operational efficiency adds a layer of confidence for investors, even as the company navigates a tougher economic landscape. With a cash reserve of $251.7 million, NU Skin appears well-positioned to invest in future growth initiatives, including the upcoming product previews and market activities in India.

However, while the EPS guidance is being maintained, the revenue shortfall could warrant caution moving forward. Investors should keep an eye on the company's ability to leverage its strong gross margins and improving efficiency to boost top-line performance in subsequent quarters.

In conclusion, while NU Skin's current situation calls for cautious optimism, strategic initiatives and continued focus on efficiency may lead to a more favorable outlook as we approach 2026. Investors may consider maintaining their position, with a watchful eye on upcoming quarterly results and market trends.